UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-Q ___________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _______ Commission File Number 001-01136 ___________________________ BRISTOL-MYERS SQUIBB COMPANY (Exac ...

Bristol Myers Squibb (BMY)业绩表现 - 公司第一季度营收达到119亿美元，同比增长5%[2] - 根据通用会计准则（GAAP），每股亏损5.89美元，非GAAP亏损为4.40美元[2] 投资者反应 - 投资者对Bristol Myers Squibb的负面反应并非源于第一季度业绩，因为公司的营收超过了市场预期，分析师也预期公司的亏损会更大[3] - 投资者对Bristol Myers Squibb的负面反应主要是因为公司的业绩指引令人失望，公司预计2024年全年的非GAAP每股收益在0.40至0.70美元之间，较之前的7.10至7.40美元有大幅下调，主要是因为收购Karuna Therapeutics和与SystImmune的合作[4]

公司裁员情况 - 布里斯托尔-迈尔斯斯奎布宣布裁员，预计裁员人数约为2,200人，占总员工数的6%[2] - 裁员是为了节省每年15亿美元，以提高公司的灵活性和决策效率[2][4] - 公司首席财务官David Elkins表示裁员旨在让公司更加灵活，加快决策速度[4] 投资者反应和市场趋势 - 裁员消息发布后，投资者对公司的第一季度财报表现不满[3] - 布里斯托尔-迈尔斯斯奎布加入了最近裁员潮，这是一个持续增长的趋势[4] 经济形势影响 - 裁员增加与当前经济形势有关，高通胀和利率上升对公司和消费者都造成了压力[5]

For the quarter ended March 2024, Bristol Myers Squibb (BMY) reported revenue of $11.87 billion, up 4.7% over the same period last year. EPS came in at -$5.89, compared to $2.05 in the year-ago quarter.The reported revenue represents a surprise of +3.57% over the Zacks Consensus Estimate of $11.46 billion. With the consensus EPS estimate being -$4.55, the EPS surprise was -29.45%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...

Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2024 Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile • First Quarter Revenues were $11.9 Billion, increasing 5% (+6% Adjusting for Foreign Exchange) ◦ Growth Portfolio Revenues were $4.8 Billion, increasing 8% (+11% Adjusting for Foreign Exchange) • Strengthened Long-Term Growth Profile Through Completion of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune Transacti ...

第一季度业绩 - 布里斯托尔迈尔斯斯奎布报告第一季度营收超出预期，主要得益于其畅销血液稀释剂Eliquis和几种新药品的销售增长[2] - 公司因最近完成的交易而出现季度亏损，但启动了一项计划，计划到2025年削减15亿美元的成本，并表示将重新投资于药物开发[3] - 布里斯托尔迈尔斯斯奎布表示将重点投资于其主要药品品牌，并将资源集中于可能带来最高回报的研发项目，以及其他努力[4]

Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2024 results on Apr 25, before market open. In the previously reported quarter, the company’s earnings beat estimates by 11.84%.Factors at PlayTotal revenues in the first quarter are likely to have been boosted by growth in in-line product revenues and new product portfolio revenues. The Zacks Consensus Estimate for total revenues in the first quarter is pegged at $11.4 billion.Increased sales of the key immuno-oncology drug Opdivo on c ...

股价表现 - BMY公司股票自2023年12月以来已经下跌了12.35%[1] 评级和股息率 - BMY公司已经被升级为买入评级，目前的股息率为5.02%[3] 业务扩张 - BMY公司通过收购等方式扩大业务规模，未来展望较为乐观[4]

These stocks pay between 3.2% and 6.7% in dividends.What's better than a high-yielding dividend stock? A high-yielding dividend stock that's trading at a dirt-cheap price. As long as the underlying business is in strong shape, buying a cheap dividend stock can help maximize your long-term profits as you benefit from both the stock rising in value, assuming it rallies, and from the dividend income you'll earn from holding it.Bristol Myers Squibb (BMY 1.30%), Verizon Communications (VZ 0.90%), and ExxonMobil ...

美国股市 - 美国股市持续上涨，尽管通货膨胀和地缘政治风险持续存在[1] - S&P 500过去12个月回报率为26%，Wilshire 5000指数在过去一年中增长了23%[1] - S&P 500目前的股息率仅为1.4%，随着市场强劲上涨，股息率下降，许多股票被高估[1] Sonoco Products - Sonoco Products是一家提供包装、工业产品和供应链服务的公司，市场包括家电、电子、饮料、建筑和食品行业[3] - Sonoco是一家股息冠军，连续41年增加股息[4] - Sonoco Products在2023年的营收下降6%，但调整后的每股收益为5.26美元，是公司历史上第二好的调整后每股收益结果[4] Bank OZK - Bank OZK是一家区域银行，提供支票、商业银行、商业贷款和抵押贷款等服务[6] - Bank OZK的股息增长历史令人印象深刻，连续54个季度提高股息[8] - Bank OZK的财务基本面强劲，第四季度贷款总额和存款分别比去年同期增长了27%和28%[9] Bristol-Myers Squibb - Bristol-Myers Squibb是一家领先的医疗保健公司，市值约为1000亿美元[13] - Bristol-Myers Squibb在2023年第四季度营收略有增长，2023年营收为450亿美元，调整后每股收益为7.51美元[14] - Bristol-Myers Squibb预计2024年营收将以低个位数增长，调整后每股收益预计在7.10至7.40美元之间[15]